News

Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium

1st November 2023 Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium Event brings together leading academics, industry representatives and investors to share progress and discuss future directions in dark genome research and the development of novel therapeutics

Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors

7th November 2022 Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors Enara Bio’s unique approach identifying Dark Antigen® candidates and cognate T cells in non-small-cell lung cancer and melanoma detailed in two posters to be presented at the 37th Society for Immunotherapy of Cancer Annual Meeting

All News

Browse our full news archives

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research 3rd November 2022 Enara Bio announces the appointment of T-cell therapy leader  Dr. Sophie Papa as Chief Medical Officer 1st February 2022 Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors 28th September 2021 Enara Bio participates in Boehringer Ingelheim’s  “Taking Cancer On” podcast series 21st June 2021 Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team 9th March 2021 Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies 12th January 2021

Publications

Scientific posters highlighting our Dark Antigens as novel immunotherapy targets for solid tumors

Identification and validation of specific Dark Antigen™ reactive TCRs

POSTER [SITC 2023] Identification and validation of specific Dark Antigen™ reactive TCRs

Identification and validation of Dark Antigens™ in multiple solid tumors

Poster (SITC 2022) Identification and validation of Dark Antigens™ in multiple solid tumors

Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Poster (SITC 2022) Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Our early research discovering immunogenic ERV-derived antigens

POSTER (SITC 2019) Our early research discovering immunogenic ERV-derived antigens

A short selection of the growing scientific literature that inspires us to shine a light on genomic dark matter

Cancer Immunology Research The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides Trends in Cell Biology The dark proteome: translation from noncanonical open reading frames Genome Research LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly

Upcoming & Recent Events

Discover the events that the Enara Bio team are attending

2nd Annual Dark Genome Symposium

November 13th - 14th 2023 London, UK

BIO-Europe

November 6th - 8th 2023 Munich, Germany

38th Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 1st - 5th 2023 San Diego, US